

Vivian D Hope

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/340989/publications.pdf>

Version: 2024-02-01

128
papers

4,982
citations

94433

37
h-index

106344

65
g-index

132
all docs

132
docs citations

132
times ranked

4313
citing authors

#	ARTICLE	IF	CITATIONS
1	Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 461-473.	1.3	5
2	Prevalence and factors associated with chronic venous insufficiency, leg ulceration and deep vein thrombosis among people who inject drugs in London, UK. <i>Drug and Alcohol Review</i> , 2022, 41, 677-685.	2.1	5
3	Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40 years on. <i>HIV Medicine</i> , 2022, 23, 978-989.	2.2	5
4	The characteristics of people who inject drugs in the United Kingdom: changes in age, duration, and incidence of injecting, 1980–2019, using evidence from repeated cross-sectional surveys. <i>Addiction</i> , 2022, 117, 2471-2480.	3.3	12
5	Systems mapping to understand complexity in the association between image and performance enhancing drugs (IPEDs) and harm. <i>International Journal of Drug Policy</i> , 2022, 107, 103801.	3.3	2
6	Image and performance enhancing drug use among men who have sex with men and women who have sex with women in the UK. <i>International Journal of Drug Policy</i> , 2021, 95, 102933.	3.3	10
7	Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs. <i>Drug and Alcohol Review</i> , 2021, 40, 586-596.	2.1	5
8	Response to Marsden et al (2020): Mitigation for the impacts on needle and syringe programmes is needed. <i>Addiction</i> , 2021, 116, 206-207.	3.3	1
9	Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations. , 2021, , 109-149.		0
10	“Belt and braces approach; added benefit and extra reassurance” a multi-stakeholder examination of the challenges to effective provision of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Northern and Central England. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 736-745.	1.2	2
11	Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. <i>Public Health</i> , 2021, 192, 8-11.	2.9	32
12	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Public Health</i> , The, 2021, 6, e309-e323.	10.0	99
13	Service provision and barriers to care for men who have sex with men engaging in chemsex and sexualised drug use in England. <i>International Journal of Drug Policy</i> , 2021, 92, 103090.	3.3	11
14	A narrative systematic review of sexualised drug use and sexual health outcomes among LGBT people. <i>International Journal of Drug Policy</i> , 2021, 93, 103187.	3.3	42
15	The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011–2018. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1452-1463.	2.0	10
16	Human enhancement drugs: Emerging issues and responses. <i>International Journal of Drug Policy</i> , 2021, 95, 103459.	3.3	6
17	Generating evidence on the use of Image and performance enhancing drugs in the UK: results from a scoping review and expert consultation by the Anabolic Steroid UK network. <i>Harm Reduction Journal</i> , 2021, 18, 107.	3.2	11
18	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. <i>Eurosurveillance</i> , 2021, 26, .	7.0	4

#	ARTICLE	IF	CITATIONS
19	Frequency of health care utilization by adults who use illicit drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	3.3	88
20	Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. <i>PLoS ONE</i> , 2020, 15, e0235350.	2.5	27
21	The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England. <i>International Journal of Drug Policy</i> , 2020, 83, 102851.	3.3	61
22	High prevalence of albuminuria amongst people who inject drugs: A cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 7059.	3.3	7
23	Incidence and treatment costs of severe bacterial infections among people who inject heroin: A cohort study in South London, England. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108057.	3.2	19
24	Psychosocial and sexual factors associated with recent sexual health clinic attendance and HIV testing among trans people in the UK. <i>BMJ Sexual and Reproductive Health</i> , 2020, 46, 116-125.	1.7	17
25	Factors associated with skin and soft tissue infections among people who inject drugs in the United Kingdom: A comparative examination of data from two surveys. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108080.	3.2	19
26	Sexually transmitted infection diagnoses, sexualised drug use and associations with pre-exposure prophylaxis use among men who have sex with men in the UK. <i>International Journal of STD and AIDS</i> , 2020, 31, 254-263.	1.1	1
27	Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London. <i>Harm Reduction Journal</i> , 2020, 17, 24.	3.2	26
28	Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming. <i>AIDS and Behavior</i> , 2020, 24, 3056-3070.	2.7	50
29	Associations with drug use and sexualised drug use among women who have sex with women (WSW) in the UK: Findings from the LGBT Sex and Lifestyles Survey. <i>International Journal of Drug Policy</i> , 2019, 74, 292-298.	3.3	11
30	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	1.9	30
31	Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 723.	2.9	43
32	The experiences of people who inject drugs of skin and soft tissue infections and harm reduction: A qualitative study. <i>International Journal of Drug Policy</i> , 2019, 65, 65-72.	3.3	18
33	Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. <i>Addiction</i> , 2019, 114, 560-570.	3.3	29
34	Psychosocial and sexual characteristics associated with sexualised drug use and chemsex among men who have sex with men (MSM) in the UK. <i>Sexually Transmitted Infections</i> , 2019, 95, 342-350.	1.9	88
35	Injecting-related health harms and overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed-methods study. <i>Harm Reduction Journal</i> , 2019, 16, 60.	3.2	28
36	Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15. <i>Drug and Alcohol Dependence</i> , 2019, 195, 40-44.	3.2	11

#	ARTICLE	IF	CITATIONS
37	Clonal expansion of community-associated meticillin-resistant Staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	7.0	17
38	Infections and risk among people who use image and performance enhancing drugs. , 2019, , 85-100.		2
39	Sexualised drug use in the United Kingdom (UK): A review of the literature. <i>International Journal of Drug Policy</i> , 2018, 55, 131-148.	3.3	149
40	Spore forming bacteria infections and people who inject drugs: Implications for harm reduction. <i>International Journal of Drug Policy</i> , 2018, 53, 45-54.	3.3	2
41	Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs. <i>Addiction</i> , 2018, 113, 1790-1801.	3.3	13
42	Identifying a typology of men who use anabolic androgenic steroids (AAS). <i>International Journal of Drug Policy</i> , 2018, 55, 105-112.	3.3	79
43	Patterns of injecting and non-injecting drug use by sexual behaviour in people who inject drugs attending services in England, Wales and Northern Ireland, 2013-2016. <i>International Journal of Drug Policy</i> , 2018, 55, 215-221.	3.3	25
44	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , 2018, 113, 545-563.	3.3	242
45	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1397-1409.	9.1	147
46	Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK. <i>Drug and Alcohol Dependence</i> , 2018, 192, 118-124.	3.2	8
47	Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it?. <i>International Journal of Drug Policy</i> , 2018, 58, 31-36.	3.3	58
48	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?. <i>Addiction</i> , 2018, 113, 1727-1738.	3.3	30
49	Sexualised drug use: LGTB communities and beyond. <i>International Journal of Drug Policy</i> , 2018, 55, 128-130.	3.3	16
50	The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C virus in people who inject drugs. <i>Journal of Hepatology</i> , 2018, 68, S146-S147.	3.7	1
51	Care and Prevent™: rationale for investigating skin and soft tissue infections and AA amyloidosis among people who inject drugs in London. <i>Harm Reduction Journal</i> , 2018, 15, 23.	3.2	20
52	A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs. <i>Eurosurveillance</i> , 2018, 23, .	7.0	8
53	Injection into the jugular vein among people who inject drugs in the United Kingdom: Prevalence, associated factors and harms. <i>International Journal of Drug Policy</i> , 2017, 46, 28-33.	3.3	11
54	The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland. <i>International Journal of Drug Policy</i> , 2017, 46, 34-40.	3.3	20

#	ARTICLE	IF	CITATIONS
55	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. The Cochrane Library, 2017, 2017, CD012021.	2.8	158
56	“Slamming”™ among men who have sex with men accessing general drug services, in response to Schmidt, AJ et al., 2016, Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS). International Journal of Drug Policy, 2017, 49, 24-25.	3.3	12
57	Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15. Drug and Alcohol Dependence, 2017, 179, 83-86.	3.2	19
58	Opiate Injection-Associated Skin, Soft Tissue, and Vascular Infections, England, UK, 1997-2016. Emerging Infectious Diseases, 2017, 23, 1400-1403.	4.3	48
59	Ongoing outbreak of invasive and non-invasive disease due to group A Streptococcus (GAS) type emm66 among homeless and people who inject drugs in England and Wales, January to December 2016. Eurosurveillance, 2017, 22, .	7.0	37
60	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. Public Health Research, 2017, 5, 1-118.	1.3	20
61	Harm reduction interventions should encompass people who inject image and performance enhancing drugs. BMJ, The, 2016, 353, i1889.	6.0	7
62	Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 331-337.	2.1	33
63	An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 2016, 111, 1616-1627.	3.3	8
64	Access to needle and syringe programs by people who inject image and performance enhancing drugs. International Journal of Drug Policy, 2016, 31, 199-200.	3.3	22
65	Not in the vein: “missed hits”™, subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol, United Kingdom. International Journal of Drug Policy, 2016, 28, 83-90.	3.3	34
66	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
67	Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection?. Eurosurveillance, 2016, 21, .	7.0	36
68	P127: Factors associated with undiagnosed hepatitis C infection among people who inject drugs and missed opportunities for testing in the United Kingdom. Journal of Viral Hepatitis, 2015, 22, 84-85.	2.0	0
69	<sc>HCV</sc> treatment rates and sustained viral response among people who inject drugs in seven <sc>UK</sc> sites: real world results and modelling of treatment impact. Journal of Viral Hepatitis, 2015, 22, 399-408.	2.0	86
70	O-08: The impact of 25 years of sero-behavioural surveillance of blood borne viral infections among people who inject drugs in the United Kingdom. Journal of Viral Hepatitis, 2015, 22, 5-5.	2.0	2
71	Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England. Epidemiology and Infection, 2015, 143, 120-131.	2.1	40
72	Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiology and Infection, 2015, 143, 132-140.	2.1	35

#	ARTICLE	IF	CITATIONS
73	Hepatitis B vaccination for people who inject drugs. <i>Lancet</i> , 2015, 385, 115-116.	13.7	1
74	Going into the groin: Injection into the femoral vein among people who inject drugs in three urban areas of England. <i>Drug and Alcohol Dependence</i> , 2015, 152, 239-245.	3.2	22
75	Sex work amongst people who inject drugs in England, Wales and Northern Ireland: Findings from a National Survey of Health Harms and Behaviours. <i>International Journal of Drug Policy</i> , 2015, 26, 429-433.	3.3	20
76	Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. <i>Epidemiology and Infection</i> , 2015, 143, 1398-1407.	2.1	16
77	Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. <i>PLoS ONE</i> , 2014, 9, e103345.	2.5	184
78	Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. <i>Epidemiology and Infection</i> , 2014, 142, 270-286.	2.1	161
79	Factors associated with the use of cleaned needles and syringes among people who inject drugs in the UK: Who should we target to minimise the risks?. <i>International Journal of Drug Policy</i> , 2014, 25, 924-927.	3.3	6
80	P1284 FACTORS ASSOCIATED WITH RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS IN THE UNITED KINGDOM: NEW FINDINGS USING AN AVIDITY TESTING ALGORITHM. <i>Journal of Hepatology</i> , 2014, 60, S518.	3.7	0
81	Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. <i>International Journal of Drug Policy</i> , 2014, 25, 34-52.	3.3	238
82	Factors associated with recent symptoms of an injection site infection or injury among people who inject drugs in three English cities. <i>International Journal of Drug Policy</i> , 2014, 25, 303-307.	3.3	26
83	Is the HCV/HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. <i>Drug and Alcohol Dependence</i> , 2013, 132, 172-181.	3.2	40
84	Factors mediating HIV risk among female sex workers in Europe: a systematic review and ecological analysis. <i>BMJ Open</i> , 2013, 3, e002836.	1.9	67
85	Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. <i>BMJ Open</i> , 2013, 3, e003207.	1.9	81
86	Infections with Spore-forming Bacteria in Persons Who Inject Drugs, 2000-2009. <i>Emerging Infectious Diseases</i> , 2013, 19, 29-34.	4.3	37
87	Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe?. <i>Eurosurveillance</i> , 2013, 18, 20648.	7.0	14
88	Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women?. <i>Sexually Transmitted Infections</i> , 2012, 88, 456-461.	1.9	12
89	Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. <i>European Journal of Public Health</i> , 2012, 22, 187-192.	0.3	79
90	A Decade of Spore-Forming Bacterial Infections Among European Injecting Drug Users: Pronounced Regional Variation. <i>American Journal of Public Health</i> , 2012, 102, 122-125.	2.7	17

#	ARTICLE	IF	CITATIONS
91	Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services. <i>Epidemiology and Infection</i> , 2012, 140, 1054-1063.	2.1	7
92	Modelling HIV in the injecting drug user population and the male homosexual population in a developed country context. <i>Epidemics</i> , 2012, 4, 48-56.	3.0	13
93	Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK. <i>Drug and Alcohol Dependence</i> , 2012, 126, 324-332.	3.2	19
94	HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. <i>BMJ Open</i> , 2012, 2, e001465.	1.9	88
95	Hepatitis C infection among recent initiates to injecting in England 2000â€“2008: Is a national hepatitis C action plan making a difference?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 55-64.	2.0	15
96	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. <i>Addiction</i> , 2011, 106, 1978-1988.	3.3	271
97	Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. <i>Journal of Viral Hepatitis</i> , 2011, 18, 262-270.	2.0	81
98	Mapping HIV-related behavioural surveillance among injecting drug users in Europe, 2008. <i>Eurosurveillance</i> , 2011, 16, .	7.0	2
99	Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. <i>Aids</i> , 2010, 24, 2849-2858.	2.2	36
100	The extent of injection site infection in injecting drug users: findings from a national surveillance study. <i>Epidemiology and Infection</i> , 2010, 138, 1510-1518.	2.1	33
101	Mapping HIV/STI behavioural surveillance in Europe. <i>BMC Infectious Diseases</i> , 2010, 10, 290.	2.9	21
102	An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales. <i>Statistical Methods in Medical Research</i> , 2009, 18, 361-379.	1.5	65
103	Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. <i>Journal of Public Health</i> , 2009, 31, 374-382.	1.8	44
104	Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?. <i>American Journal of Epidemiology</i> , 2009, 170, 352-360.	3.4	50
105	Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. <i>BMC Infectious Diseases</i> , 2008, 8, 120.	2.9	97
106	Epidemic of severe <i>Streptococcus pyogenes</i> infections in injecting drug users in the UK, 2003â€“2004. <i>Clinical Microbiology and Infection</i> , 2008, 14, 1002-1009.	6.0	38
107	Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2008, 15, 250-254.	2.0	102
108	A comparison between the force of infection estimates for bloodâ€“borne viruses in injecting drug user populations across the European Union: a modelling study. <i>Journal of Viral Hepatitis</i> , 2008, 15, 809-816.	2.0	29

#	ARTICLE	IF	CITATIONS
109	Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?. <i>Journal of Viral Hepatitis</i> , 2007, 14, 584-591.	2.0	21
110	Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. <i>Journal of Viral Hepatitis</i> , 2007, 14, 645-652.	2.0	86
111	Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?. <i>Journal of Viral Hepatitis</i> , 2007, 14, 653-660.	2.0	22
112	Estimating prevalence of injecting drug use: a comparison of multiplier and capture-recapture methods in cities in England and Russia. <i>Drug and Alcohol Review</i> , 2006, 25, 131-140.	2.1	34
113	Modelling the hepatitis B vaccination programme in prisons. <i>Epidemiology and Infection</i> , 2006, 134, 231-242.	2.1	18
114	Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. <i>BMC Infectious Diseases</i> , 2006, 6, 93.	2.9	70
115	Groin injecting in the context of crack cocaine and homelessness: From "risk boundary" to "acceptable risk"? <i>International Journal of Drug Policy</i> , 2006, 17, 164-170.	3.3	45
116	Monitoring the effectiveness of HIV and STI prevention initiatives in England, Wales, and Northern Ireland: where are we now?. <i>Sexually Transmitted Infections</i> , 2006, 82, 4-10.	1.9	18
117	HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. <i>Aids</i> , 2005, 19, 1207-1214.	2.2	41
118	Capturing crack cocaine use: estimating the prevalence of crack cocaine use in London using capture-recapture with covariates. <i>Addiction</i> , 2005, 100, 1701-1708.	3.3	55
119	Modelling the characteristics of the male injecting drug user population in England and Wales. <i>International Journal of Drug Policy</i> , 2005, 16, 176-182.	3.3	7
120	Wound botulism in injectors of drugs: upsurge in cases in England during 2004. <i>Eurosurveillance</i> , 2005, 10, 5-6.	7.0	33
121	Wound botulism in injectors of drugs: upsurge in cases in England during 2004. <i>Eurosurveillance</i> , 2005, 10, 172-4.	7.0	12
122	Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 766-771.	3.7	86
123	The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. <i>Addiction</i> , 2004, 99, 1430-1438.	3.3	31
124	Sustained increase in the sharing of needles and syringes among drug users in England and Wales. <i>Aids</i> , 2002, 16, 2494-2496.	2.2	15
125	Relation between information and advice provision to male GUM clinic attendees and sexual orientation and ethnic group. <i>Sexually Transmitted Infections</i> , 2000, 76, 198-202.	1.9	1
126	The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. <i>Epidemiology and Infection</i> , 1998, 121, 381-386.	2.1	30

#	ARTICLE	IF	CITATIONS
127	The HIV epidemic in injecting drug users. Communicable Disease Report CDR Review, 1997, 7, R128-30.	0.3	5
128	A comparison of HIV related advice in genitourinary medicine clinics with different histories.. Sexually Transmitted Infections, 1996, 72, 286-289.	1.9	1